Physician profile
Santa Nandi
NPI 1679677868
$2,014.36
in general payments reported to CMS, 2019-2025
17 companies · $667 in 2025
The $667 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $148 · 2022: $334 · 2023: $369 · 2024: $497 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,532.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $589.89 | 2022-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $312.22 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $186.49 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $168.19 | 2021-2024 | Talicia |
| Intercept Pharmaceuticals, INC. | $153.21 | 2021-2025 | Ocaliva |
| Pfizer INC. | $110.25 | 2023-2025 | |
| Genzyme Corporation | $99.07 | 2024-2025 | |
| Lilly USA, LLC | $70.69 | 2024-2025 | Omvoh |
| Celgene Corporation | $50.53 | 2023 | Zeposia |
| Madrigal Pharmaceuticals | $49.74 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $44.93 | 2022-2025 | Entyvio |
| Alfasigma USA, INC. | $44.10 | 2021 | |
| Qol Medical, LLC | $42.09 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $27.84 | 2025 | Dupixent |
| Evoke Pharma, INC. | $26.71 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $23.35 | 2025 | Wegovy |
| Exact Sciences Corporation | $15.06 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Santa Nandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.